Compare CHWY & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | TWST |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.2B |
| IPO Year | 2019 | 2018 |
| Metric | CHWY | TWST |
|---|---|---|
| Price | $21.20 | $154.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 13 |
| Target Price | $28.64 | ★ $168.25 |
| AVG Volume (30 Days) | ★ 7.0M | 2.8M |
| Earning Date | 12-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $12,601,500,000.00 | $376,572,000.00 |
| Revenue This Year | $7.32 | $21.17 |
| Revenue Next Year | $6.75 | $20.24 |
| P/E Ratio | $49.71 | ★ N/A |
| Revenue Growth | 6.24 | ★ 20.32 |
| 52 Week Low | $17.40 | $23.30 |
| 52 Week High | $37.34 | $219.71 |
| Indicator | CHWY | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 49.20 |
| Support Level | $19.78 | $122.05 |
| Resistance Level | $22.31 | $155.44 |
| Average True Range (ATR) | 0.78 | 13.90 |
| MACD | 0.09 | 1.25 |
| Stochastic Oscillator | 56.77 | 45.60 |
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.